£8 million funding for new start-up TopiVert
Imperial Innovations Group plc and SV Life Sciences have committed to invest £8 million in a new start-up company TopiVert, which will focus on developing topical medicines for inflammatory diseases of the eye and gut.
TopiVert has licensed NSKI (narrow spectrum kinase inhibitor) related intellectual property from RespiVert Ltd., a former Imperial Innovations portfolio company acquired by Janssen Biotech, Inc. (formerly known as Centocor Ortho Biotech Inc.) in 2010, for TopiVert’s exclusive use in discovering and developing NSKIs for inflammatory diseases of the eye and gut. Both participants in this funding round were also investors in RespiVert.
TopiVert will enter into an exclusive drug discovery collaboration with RespiVert aimed at identifying new NSKIs. TopiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of inflammatory diseases of the eye and gut, such as uveitis and inflammatory bowel disease, while RespiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of other indications, such as inflammatory diseases of the lungs.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
The Trap Snaps Shut - Researchers isolate the substance that causes Venus flytraps to close
Evonik to market and develop new drug delivery platform for mRNA and gene therapy - Evonik and Stanford University sign research collaboration
For better leukemia therapies: spin-off Cimeio partners with pharmaceutical company Kyowa Kirin - “Our method, which involves equipping blood cells with a kind of protective shield and then targeting and removing diseased cells, smooths the way for treatments that could not have been used in that way before”
Energy sensor as potential target for cancer drugs identified
Companies opt for CMOs offering high-quality services
